INDIAN HEALTHCARE SYSTEM | HEALTHCARE SYSTEM OF INDIA | NEWS | BLOGS | IPHARMACENTER
DEMOGRAPHICS The constitution of India ensures the "right to health" for every citizen. It is the responsibility of the state governments to provide health care services to citizens. The funding for healthcare in India is 3% of GDP and is continuously decreasing since (3.75% in 2013). Government spending currently accounts for 1% of GDP, and the Indian government aims to increase it to 2.5% by 2025. The infant mortality rate was reduced from 88/1,000 in 1990 to 32/1,000 in 2
FDA Grants Second Approval to Sotyktu in the US; approved for Adults with Active Psoriatic Arthritis
The U.S. Food and Drug Administration (FDA) has granted approval for Sotyktu (deucravacitinib), an oral, selective inhibitor of tyrosine kinase 2 (TYK2), for use in adult patients with active psoriatic arthritis (PsA). This marks the first approval of a TYK2 inhibitor for this condition in the United States. The decision was supported by positive outcomes from two pivotal Phase 3 clinical studies, POETYK PsA-1 and POETYK PsA-2, which evaluated the efficacy and safety of deucr
Top 10 Pharmaceutical Companies by Revenue 2025: Best-Selling Drugs Analysis | iPharmaCenter
Top pharmaceutical companies by revenues in 2025. The revenues are captured from the official websites of pharmaceutical companies
Johnson and Johnson approved Tecvayli plus Darzalex Faspro for 2L multiple myeloma | iPharmaCenter
Johnson & Johnson has received U.S. FDA approval for the combination of Tecvayli (teclistamab) and Darzalex Faspro (daratumumab and hyaluronidase) for adults with relapsed or refractory multiple myeloma after at least one prior line of therapy that included a proteasome inhibitor and an IMiD. The FDA reached this decision 55 days after submission, making it the third approval granted through the Commissioner’s National Priority Voucher (CNPV) pilot program. The regimen can no
Roche's petrelintide showed benefits but early results show inferior benefits over Lilly's eloralintide | iPharmaCenter
Roche reported encouraging mid‑stage results for petrelintide, a once‑weekly amylin analogue being developed as a novel option for people with overweight and obesity. In the 42‑week ZUPREME‑1 trial, which enrolled 493 adults with a mean BMI of about 37 kg/m² on background diet and exercise, all five petrelintide dose regimens achieved statistically significant and clinically meaningful weight loss versus placebo at week 28, meeting the primary endpoint. Weight reduction conti
American Academy of Neurology (AAN) Annual Meeting 2026 | iPharmaCenter
Roche’s BTK inhibitor fenebrutinib delivers strong efficacy in relapsing multiple sclerosis, opening up a potential multi‑billion‑dollar revenue opportunity for the company Roche’s BTK inhibitor fenebrutinib has generated a third consecutive Phase III success in multiple sclerosis, strengthening its positioning as a potential first-in-class option across both relapsing and progressive forms of the disease. What clinical benefits fenebrutinib show in clinical trials? In the la